

DT12 Rec'd PCT/PTO 22 JUL 2004

PTO/SB/08A (02-03)

Approved for use through 04/30/2003. OMB 0651-0031  
Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

|       |   |    |   |
|-------|---|----|---|
| Sheet | 1 | of | 2 |
|-------|---|----|---|

**Complete if Known**

|                        |                  |
|------------------------|------------------|
| Application Number     | Not Yet Known    |
| Filing Date            | Herewith         |
| First Named Inventor   | BURIONI, Roberto |
| Art Unit               | Not Yet Known    |
| Examiner Name          | Not Yet Known    |
| Attorney Docket Number | 937-PCT-US       |

**U. S. PATENT DOCUMENTS**

[illegible]

## FOREIGN PATENT DOCUMENTS

| FOREIGN PATENT DOCUMENTS |                       |   |                  |   |   |                |
|--------------------------|-----------------------|---|------------------|---|---|----------------|
| Examiner Initials*       | Cite No. <sup>1</sup> | Foreign Patent Document   | Publication Date | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T <sup>6</sup> |
|                          |                       | Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known) | MM-DD-YYYY       |   |   |                |
| /ZL/                     | 4                     | WO 00/05266   | 02-03-2000       | Reiter, et al.                                  |   |                |
| /ZL/                     | 5                     | WO 02/055560 A2   | 07-18-2002       | Schofield, et al.                               |   |                |
|                          |                       |   |                  |   |   |                |
|                          |                       |   |                  |   |   |                |
|                          |                       |   |                  |   |   |                |
|                          |                       |   |                  |   |   |                |
|                          |                       |   |                  |   |   |                |

**Examiner  
Signature**

/Zachariah Lucas/

Date \_\_\_\_\_

**Considered**

02/27/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |                          |                  |
|--|---|--------------------------|------------------|
| Substitute for form 1449/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |   | <b>Complete if Known</b> |                  |
|  |   | Application Number       | Not Yet Known    |
|  |   | Filing Date              | Herewith         |
|  |   | First Named Inventor     | BURIONI, Roberto |
|  |   | Art Unit                 | Not Yet Known    |
|  |   | Examiner Name            | Not Yet Known    |
| Sheet  | 2 | of                       | 2                |
|  |   | Attorney Docket Number   | 937-PCT-US       |

| OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS |                          |   |                |
|---|--------------------------|---|----------------|
| Examiner<br>Initials*                           | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
| /ZL/  | 1                        | PCT International Search Report for BURIONI, Roberto, Int'l Application No. PCT/IT03/00032, Filed January 29, 2003, Dated August 6, 2003  |                |
| /ZL/  | 2                        | BURIONI, et al., "Nonneutralizing Human Antibody Fragments against Hepatitis C Virus E2 Glycoprotein Modulate Neutralization of Binding Activity of Human Recombinant Fabs." Virology, Vol. 288, 29-30 (2001)   |                |
| /ZL/  | 3                        | ALLANDER, et al., "Recombinant Human Monoclonal Antibodies against Different Conformational Epitopes of the E2 Envelope Glycoprotein of Hepatitis C Virus That Inhibit Its Interaction with CD81." Journal of General Virology, Vol. 81, 2451-2459 (2000)       |                |
|   |                          |   |                |
|   |                          |   |                |
|   |                          |   |                |
|   |                          |   |                |
|   |                          |   |                |
|   |                          |   |                |
|   |                          |   |                |
|   |                          |   |                |


|                       |                   |                    |            |
|-----------------------|-------------------|--------------------|------------|
| Examiner<br>Signature | /Zachariah Lucas/ | Date<br>Considered | 02/27/2007 |
|-----------------------|-------------------|--------------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (02-03)  
Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

### Complete if Known

|                        |                  |
|------------------------|------------------|
| Application Number     | 10/502,307       |
| Filing Date            | July 22, 2004    |
| First Named Inventor   | BURIONI, Roberto |
| Art Unit               | Not Yet Known    |
| Examiner Name          | Not Yet Known    |
| Attorney Docket Number | 937-PCT-US       |

Sheet 1 of 1

### OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

| Examiner<br>Initials* | Cite<br>No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.   | T <sup>2</sup> |
|-----------------------|--------------------------|---|----------------|
| /ZL/                  | 1                        | 1. ROSA D., et al., "A Quantitative Test To Estimate Neutralizing Antibodies to the Hepatitis C Virus: Cytofluorimetric Assessment of Envelope Glycoprotein 2 Binding to Target Cells." Proceedings of the National Academy of Sciences of USA, National Academy of Science. Washington. US, Vol. 93, no. 3 (1996-03-01). |                |
|                       |                          |   |                |
|                       |                          |   |                |
|                       |                          |   |                |
|                       |                          |   |                |
|                       |                          |   |                |
|                       |                          |   |                |
|                       |                          |   |                |
|                       |                          |   |                |
|                       |                          |   |                |
|                       |                          |   |                |

|                       |                   |                    |            |
|-----------------------|-------------------|--------------------|------------|
| Examiner<br>Signature | /Zachariah Lucas/ | Date<br>Considered | 02/26/2007 |
|-----------------------|-------------------|--------------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.